YesWeHack Raises 26 Million Euros to Accelerate Its Growth and International Expansion
YesWeHack, the global Bug Bounty and vulnerability management platform, announces a €26 million Series C funding round.
In a world where cyber risks are more strategic and complex than ever, YesWeHack will use this funding to invest in Artificial Intelligence, launch new innovative solutions and expand its international growth.
The round is led by Wendel, alongside new investors such as Adelie and Seventure Partners, as well as reinvestment from Bpifrance, Open CNP* and Eiffel Investment Group. YesWeHack is also delighted to welcome Renaud Deraison, Co-Founder of Tenable and Senior Advisor to Wendel Growth, to its Board of Directors.
YesWeHack is the leading security testing solution for organisations of all sizes. Its Bug Bounty platform mobilises a community of tens of thousands ethical hackers to test the security of its customers in an agile and cost-effective way, thus reducing their attack surface.
With more than 500 customers across 40 countries, YesWeHack covers all business sectors, including:
- 70% of “CAC 40” ** companies
- Global organisations such as Louis Vuitton, Decathlon and Tencent
- Telecoms companies such as Orange, Ooredoo and Telenor
- Unicorns such as Contentsquare, Doctolib and Blablacar
- Public institutions in countries such as France, Spain, Canada and Singapore
Since its last funding round in 2021, YesWeHack has increased by six times its annual recurring revenue and tripled the number of ethical hackers registered on its platform. The company has also developed integrated pentest and attack surface management solutions, offering customers a unified approach to monitoring their online risks and vulnerabilities.
Guillaume Vassault-Houlière, CEO and Co-Founder of YesWeHack, commented: “This funding round is a vote of confidence in our commitment to excellence and our ambitious vision. Thanks to this investment, YesWeHack will deliver even higher levels of customer satisfaction and continue developing innovative solutions in one of the most dynamic segments of cybersecurity. We would like to thank our investors, both longstanding and new, and are honoured by their trust.”
Antoine Izsak, Head of Growth Equity at Wendel, said: “Bug bounty is now recognised as a must by some of the companies most exposed to the cyber threat. We are delighted to be working with the European leader YesWeHack, which stands out for its quality of service, compliance with regulations and the relevance of its technological roadmap for customers who are increasingly overwhelmed by the growing volume of vulnerabilities."
Renaud Deraison, Co-Founder of Tenable, Senior Advisor to Wendel Growth and new member of the Board of Directors added:"YesWeHack's community of experts is one of the most qualified in the world to continuously test the security of its customers' digital infrastructure. I'm honoured to join YesWeHack's Board of Directors and look forward to contributing to the company's mission alongside Guillaume and his team."
*The Corporate Venture Capital fund of CNP Assurances.
**The CAC 40 is Paris’ main stock market index.
About YesWeHack
YesWeHack is a leading Bug Bounty and Vulnerability Management Platform. Founded by ethical hackers in 2015, YesWeHack connects organisations worldwide to tens of thousands of ethical hackers, who uncover vulnerabilities in websites, mobile apps, connected devices and digital infrastructure.
Our Bug Bounty Programs benefit from in-house triage, personalised support, a customisable model and results-based pricing. Clients include Tencent, Swiss Post, Telenor, Ooredoo, Orange, the French Ministry of Armed Forces and several other governments worldwide.
The YesWeHack platform offers a range of integrated, API-based solutions: Bug Bounty (crowdsourcing vulnerability discovery), Vulnerability Disclosure Policy (creating and managing a secure channel for external vulnerability reporting), Pentest Management (managing pentest reports from all sources) and Attack Surface Management (continuously mapping online exposure and detecting attack vectors).
For more information, visit: www.yeswehack.com
This transaction was carried out with the expert support of Trachet Ltd.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610793319/en/
Contact information
Press
press@yeswehack.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 18:00:00 EEST | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm
Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 01:40:00 EEST | Press release
Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing
Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 21:46:00 EEST | Press release
Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s
Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 17:20:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 13:00:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom